# FORM 4

may continue. See

Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
OMB Number:	3235-0287					
Estimated average but	ırden					
hours per response	0.5					

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *- LEPORE PATRICK G				Matinas BioPharma Holdings, Inc. [MTNB]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)XDirector10% Owner				
(Last) (First) (Middle) C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH SUITE 302				3. Date of Earliest Transaction (Month/Day/Year) 11/01/2018						Officer (give	e title below)	Other	(specify below)		
(Street) BEDMINSTER, NJ 07921				4. If Amendment, Date Original Filed(Month/Day/Year)					_X_	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person					
(Cit	y)	(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											
1.Title of S (Instr. 3)	Security		2. Transaction Date (Month/Day/Year)	2A. Dec Executi any (Month	ion I	Date, if Co (In		(A (In	Securities Acq ) or Disposed of str. 3, 4 and 5)	of (D) Own Trai		Securities Being Reported	d O'FG D'or	wnership of orm: Be rect (D) Ov Indirect (Ir	eneficial wnership
Reminder:	Report on a	separate line for eac	Table II -	Derivati	ve S	ecurities A	Acqu	Persons contain form dis	s who responed in this for splays a curred of, or Benevertible secur	m are not ently valid eficially Ov	required d OMB co	to respon	d unless the	SEC 147	74 (9-02)
1. Title of Derivative Security (Instr. 3)	Conversion	e (Month/Day/Year)	Execution Date, if	Code				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	Form of Derivative Security: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(msu. 4)	(msu. 4)	
Stock option (right to buy)	\$ 0.74	11/01/2018		A		128,299		(1)	10/31/2028	Common Stock	128,299	\$ 0	128,299	D	

### **Reporting Owners**

Donastina Coman Nama / Addison	Relationships					
Reporting Owner Name / Address		10% Owner	Officer	Other		
LEPORE PATRICK G C/O MATINAS BIOPHARMA HOLDINGS, INC. 1545 ROUTE 206 SOUTH SUITE 302 BEDMINSTER, NJ 07921	X					

### **Signatures**

/s/ Jerome D. Jabbour, attorney-in fact for Patrick G. LePore	11/05/2018	
Signature of Reporting Person	Date	

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly (1) installments over a period of 12 months commencing on December 1, 2018. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.